SREBF1 and hepatocellular carcinoma: To determine whether SREBP1 targeting inhibitors combined with MARCH8 can also inhibit the progression of HCC in vivo, nude mouse orthotopic liver tumor models and subcutaneous tumor models were developed by injecting vector Huh7 cells or or MARCH8-overexpressing Huh7 cells (Fig. 9J).